

04/07/2005

10/612,497

FOREIGN PATENT DOCUMENTS

I.O.

European Patent 0 239 400, (Winter) published August 3, 1994.

OTHER DOCUMENTS

Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," *Nature*, 321:522-525 (1986).

Morrison, "Transfectomas provide novel chimeric antibodies," *Science*, 229:1202-1207 (1985).

Oi et al., "Chimeric antibodies," *Biotechniques*, 4(3):214-221 (1986).

Neuberger et al., "A hapten-specific chimaeric IgE antibody with human physiological effector function," *Nature*, 314:268-270 (1985).

O'Kennedy et al., "Antibody engineering: an overview," *Essays in Biochemistry*, 46:59-75 (1991).

Parren, "Preparation of genetically engineered monoclonal antibodies for human immunotherapy," *Human Antibodies and Hybridomas*, 3:137-145 (1992).

Riechmann et al., "Reshaping human antibodies for therapy," *Nature*, 332:323-327 (1988).

Vaswani et al., "Humanized antibodies as potential therapeutic drugs," *Annals of Allergy, Asthma & Immunology*, 81:105-119 (1998).

Verhoeyen et al., "Reshaping human antibodies: grafting an antilysozyme activity," *Science*, 239:1534-1536 (1988).

I.O.

Wu, "From esoteric theory to therapeutic antibodies," *Applied Biochemistry and Biotechnology*, 47(2/3):107-118 (1994).

Ilia Ouspenski 06/27/2005

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
		APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
		FILING DATE July 1, 2003	GROUP 1446 1644

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTS

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
I.O.	6,255,458	07/03/01	Lonberg et al.	530	388.15	
	6,207,156	03/27/01	Kuchroo et al.	424	154.1	
	6,162,983	12/19/00	Kucherlapati et al.	800	18	
	6,150,584	11/21/00	Kucherlapati et al.	800	18	
	6,114,598	09/05/00	Kucherlapati et al.	800	18	
	6,075,181	06/13/00	Kucherlapati et al.	800	25	
	6,051,227	04/18/00	Allison et al.	424	144.1	
	5,977,318	11/02/99	Linsley et al.	530	388.1	
	5,968,510	10/19/99	Linsley et al.	424	141.1	
	5,938,598	08/17/99	Kucherlapati et al.	800	25	
	5,916,771	06/29/99	Hori et al.	435	69.6	
	5,855,887	01/05/99	Allison et al.	424	144.1	
	5,827,690	10/27/98	Meade et al.	435	69.6	
	5,814,318	09/29/98	Lonberg et al.	424	184.1	
	5,811,097	09/22/98	Allison et al.	424	144.1	
	5,789,650	08/04/98	Lonberg et al.	800	2	
	5,789,215	08/04/98	Berns et al.	435	172.3	
	5,777,085	07/07/98	Co et al.	530	388.23	
	5,773,253	06/30/98	Linsley et al.	435	69.7	
	5,770,429	06/23/98	Lonberg et al.	435	240.2	
	5,770,197	06/23/98	Linsley et al.	424	134.1	
	5,756,687	05/26/98	Denman et al.	530	412	
	5,750,172	05/12/98	Meade et al.	426	580	
	5,741,957	04/21/98	Deboer et al.	800	2	
	5,733,743	03/31/98	Johnson et al.	435	69.1	
	5,721,367	02/24/98	Kay et al.	800	2	
	5,714,350	02/03/98	Co et al.	435	69.6	
I.O.	5,703,057	12/30/97	Johnston et al.	514	44	

EXAMINER

Iliia Ouspenski

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
INFORMATION DISCLOSURE STATEMENT BY APPLICANTS		APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
		FILING DATE July 1, 2003	GROUP 4116 1644

I.O.	5,697,902	12/16/97	Goldenberg	604	49	
	5,693,792	12/02/97	Torii et al.	540	358	
	5,693,761	12/02/97	Queen et al.	536	23.53	
	5,661,016	08/26/97	Lonberg et al.	435	172.3	
	5,648,471	07/15/97	Buttram et al.	424	1.49	
	5,643,763	07/01/97	Dunn et al.	435	91.1	
	5,633,425	05/27/97	Lonberg et al.	800	2	
	6,625,128	04/29/97	Lonberg et al.	800	2	
	5,612,205	03/18/97	Kay et al.	435	172.3	
	5,591,669	01/07/97	Krimpenfort et al.	800	2	
	5,585,089	12/17/96	Queen et al.	424	133.1	
	5,569,825	10/29/96	Lonberg et al.	800	2	
	5,545,807	08/13/96	Surani et al.	800	2	
	5,545,806	08/13/96	Lonberg et al.	800	2	
	5,530,101	06/25/96	Queen et al.	530	387.2	
	5,434,131	07/18/95	Linsley et al.	514	2	
	5,194,594	03/16/93	Khawli et al.	530	391.5	
	5,151,510	09/29/92	Stec et al.	536	27	
	RE 35,500	05/06/97	Rhodes	424	1.49	
	6,102,990	04/07/93	Rhodes	530	391.5	
	5,101,827	04/07/92	Goldenberg	128	653.4	
	4,959,455	09/25/90	Clark et al.	530	351	
	4,921,040	03/27/90	Kaufman et al.	435	69.6	
	4,816,397	03/28/89	Boss et al.	435	68	
	4,740,461	04/26/88	Kaufman	435	68	
	4,735,210	04/05/88	Goldenberg	128	654	
	4,683,202	07/28/87	Mullis	435	91	
	4,683,195	07/28/87	Mullis et al.	435	6	
	4,681,581	07/21/87	Coates	604	391	
	4,399,216	08/16/83	Axel et al.	435	6	
I.O.	2002/0086014	07/04/02	Korman et al.	424	144.1	

EXAMINER

Ilion Ouspenski

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
		APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
		FILING DATE July 1, 2003	GROUP 4118 1644

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
I.O.	CA 2,205,680	11/16/98	Canada	A61K	38/17		
	EP 0 546 073	06/16/93	Europe	C12N	15/13		
	EP 0 463 151	01/02/92	Europe	C12N	15/00		
	EP 0 338 841	10/25/89	Europe	C12N	15/00		
	EP 0 323 997	07/19/89	Europe	C12N	15/12		
	EP 0 256 055	02/24/88	Europe	C12N	15/52		
	EP 0 216 846	04/08/87	Europe	C12N	15/00		
	WO 01/14424	03/01/01	PCT	C07K	16/00		
	WO 00/32231	06/08/00	PCT	A61K	39/395		
	WO 98/50433	11/12/98	PCT	C07K	16/28		
	WO 98/46896	10/22/98	PCT	G01N	33/53		
	WO 98/42752	10/01/98	PCT	C07K	16/28		
	WO 98/24893	06/11/98	PCT	C12N	15/00		
	WO 98/24884	06/11/98	PCT	C12N	5/00		
	WO 97/38137	10/16/97	PCT	C12Q	1/68		
	WO 97/20574	06/12/97	PCT	A61K	38/16		
	WO 97/13852	04/17/97	PCT	C12N	15/00		
	WO 96/34098	10/31/96	PCT	C12N	15/00		
	WO 96/33735	10/31/96	PCT	A61K	39/00		
	WO 96/22380	07/25/96	PCT	C12N	15/87		
	WO 96/14436	05/17/96	PCT	C12Q	1/68		
	WO 95/33770	12/14/95	PCT	C07K	14/705		
	WO 95/24217	09/14/95	PCT	A61K	39/395		
	WO 95/03408	02/02/95	PCT	C12N	15/12		
	WO 95/01994	01/19/95	PCT	C07K	14/705		
	WO 94/29444	12/22/94	PCT	C12N	15/11		
	WO 94/25585	11/10/94	PCT	C12N	15/00		
I.O.	WO 94/02802	02/03/94	PCT	C12N	15/00		

EXAMINER

Ilan Ouspenski

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
		APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
		FILING DATE July 1, 2003	GROUP 1116 1644

I.O.	WO 94/00569	01/06/94	PCT	C12N	15/00		
	WO 93/12227	06/24/93	PCT	C12N	15/00		
	WO 93/00431	01/07/93	PCT	C12N	15/12		
	WO 92/22670	12/23/92	PCT	C12Q	1/68		
	WO 92/22647	12/23/92	PCT	C12N	15/00		
	WO 92/22645	12/23/92	PCT	C12N	15/00		
	WO 92/03918	03/19/92	PCT	A01H	1/00		
	WO 91/10741	07/25/91	PCT	C12P	21/06		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Alegre et al., "Regulation of surface and intracellular expression of CTLA4 on mouse T cells," <i>J. Immunol.</i> , 157:4762-4770 (1996)
	Allison & Krummel, "The Yin and Yang of T cell costimulation," <i>Science</i> , 270:932-933 (1995)
	Balzano et al., "CTLA-4 and CD28: Similar proteins, neighbouring genes," <i>Int'l J Cancer Suppl.</i> , 7:28-32 (1992)
	Barker and Dayhoff, "Detecting distant relationships: computer methods and results," <i>Atlas of Protein Sequence and Structure</i> , pp. 101-110 (Volume 5, National Biomedical Research Foundation (1972))
	Blair et al., "Cutting edge: CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-XL induction," <i>J Immunol</i> , 160:12-15 (1998)
	Blake and Litzi-Davis, "Evaluation of peptide libraries: An iterative strategy to analyze the reactivity of peptide mixtures with antibodies," <i>BioConjugate Chem.</i> , 3:510-513 (1992)
	Boussiotis et al., "Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation," <i>Proc Natl Acad Sci USA</i> , 90:11059-11063 (1993)
	Bowie et al., "A method to identify protein sequences that fold into a known three-dimensional structure," <i>Science</i> , 253:164-170 (1991)
	Bruggemann et al., "A repertoire of monoclonal antibodies with human heavy chains from transgenic mice," <i>PNAS USA</i> , 86:6709-6713 (1989)
	Bruggemann and Neuberger, "Generation of antibody repertoires in transgenic mice," <i>Methods: A companion to Methods in Enzymology</i> , 2:159-165 (1991)
I.O.	Bruggemann et al., "Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus," <i>Eur. J. Immunol.</i> 21:1323-1326 (1991)

EXAMINER

Ilia Ouspenski

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/812,497
INFORMATION DISCLOSURE STATEMENT BY APPLICANTS		APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
		FILING DATE July 1, 2003	GROUP 4116 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
I.O.	Bruggemann, M. and Neuberger, M.S. "Strategies for expressing human antibody repertoires in transgenic mice," <i>Immunology Today</i> , 17:391-397 (1996)
	Brunet et al., "A new member of the immunoglobulin superfamily - CTLA-4," <i>Nature</i> , 328:267-270 (1987)
	Bumpers et al., "Consistent hepatic metastasis of human colorectal cancer in severe combined immunodeficient mice," <i>J. Surgical Res.</i> , 61:282-288 (1996)
	Castan et al., "Accumulation of CTLA-4 expressing T lymphocytes in the germinal centres of human lymphoid tissues," <i>Immunology</i> , 90:265-271 (1997)
	Chen et al., "Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules Cd28 and CTLA-4," <i>Cell</i> 71:1093-1102 (1992)
	Chen et al., "Immunoglobulin gene rearrangement in B-cell deficient mice generated by targeted deletion of the JH locus," <i>International Immunology</i> , 5:647-656 (1993)
	Chen et al., "Intracellular antibodies as a new class of therapeutic molecules for gene therapy," <i>Human Gene Therapy</i> , 5:595-601 (1994)
	Chiswell and McCafferty, "Phage antibodies: will new 'colidonal' antibodies replace monoclonal antibodies?" <i>TIBTECH</i> , 10:80-84 (1992)
	Choi et al., "Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome," <i>Nature Genetics</i> , 4:117-123 (1993)
	Chothia & Lesk, "Canonical structures for the hypervariable regions of immunoglobulins," <i>J. Mol. Biol.</i> , 196:901-917 (1987)
	Chothia et al., "Conformations of immunoglobulin hypervariable regions," <i>Nature</i> , 342:877-883 (1989)
	Chuang et al., "Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression," <i>J. Immunol.</i> , 159:144-151 (1997)
	Colligan et al., "Unit 2.1, "Enzyme-linked immunosorbent assays," <i>Current protocols in immunology</i> , 2.1.1-2.1.22 (1994)
	Cwirla et al., "Peptides on phage: a vast library of peptides for identifying ligands," <i>PNAS USA</i> , 87:6378-6382 (1990)
	Dariavach et al., "Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains," <i>Eur. J. Immunol.</i> , 18:1901-1905 (1988)
I.O.	Dayhoff, "Survey of new data and computer methods of analysis," <i>Atlas of Protein Sequence and Structure</i> , pp. 1-10 (Volume 5, Supplement 2, National Biomedical Research Foundation (1976))

EXAMINER

Dier Ouspenski

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
INFORMATION DISCLOSURE STATEMENT BY APPLICANTS		APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
		FILING DATE July 1, 2003	GROUP 4416 1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
I.O.	de Boer et al., "Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells," <i>Eur J Immunol</i> , 23:3120-3125 (1993)
	Evans et al., "Design of nonpeptidic ligands for a peptide receptor: cholecystokinin antagonists," <i>J. Med. Chem.</i> , 30:1229 (1987)
	Fallarino et al., "B7-1 Engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28," <i>J Exp Med</i> , 188:205-210 (1998)
	Fanger et al., "Production and use of anti-FcR bispecific antibodies," <i>Immunol Methods</i> , 4:72-81 (1994)
	Fauchere, J., "Elements for the rational design of peptide drugs," <i>Adv. Drug Res.</i> , 15:29-69 (1986)
	Fishwild et al., "High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice," <i>Nature Biotech.</i> , 4:845-851 (1996)
	Foster et al., "Molecular Mechanisms and Selective Influences That Shape the Kappa Gene Repertoire of IgM ⁺ B Cells," <i>J. Clin. Invest.</i> , 99:1614-27 (1997).
	Freeman et al., "Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production," <i>J Exp Med.</i> , 178:2185-192 (1993)
	Freeman et al., "Uncovering of functional alternative CTLA-4 counter-receptor in B7- deficient mice," <i>Science</i> , 262:907-909 (1993)
	Freeman et al., "The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor," <i>J Immunol</i> , 161:2708-2715 (1998)
	Fry et al., "Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor," <i>Proc Natl Acad Sci USA</i> , 95:12022-12027 (1998)
	Furet et al., "Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411," <i>J of Computer-Aided Molecular Design</i> , 9:465-472 (1995)
	Galfre and Milstein, "Preparation of monoclonal antibodies: strategies and procedures," <i>Methods Enzymol.</i> , 73:3-46 (1981)
	Ginalski et al., "Modelling of active forms of protein kinases: p38 - a case study," <i>Acta Biochimica Polonica</i> , 44:557-564 (1997)
I.O.	Gorman et al., "The rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection," <i>Proc Natl Acad Sci USA</i> , 79:6777 (1982)

EXAMINER

Ilia Ouspenski

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANTS	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
	APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
	FILING DATE July 1, 2003	GROUP 4418 1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
I.O.	Green et al., "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs," <i>Nature Genetics</i> , 7:13-21 (1994)
	Green and Jakobovits, "Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes," <i>J. Exp. Med.</i> , 188:483-495 (1998)
	Gribben et al., "CTLA4 mediates antigen specific apoptosis of human T cells," <i>Proc. Natl. Acad. Sci.</i> , 92:811-815 (1995)
	Grosschedl and Baltimore, "Cell-type specificity of immunoglobulin gene expression is regulated by at least three DNA sequence elements," <i>Cell</i> , 41:885-897 (1985)
	Hanes and Plückthun, "In vitro selection and evolution of functional proteins by using ribosome display," <i>Proc Natl Acad Sci USA</i> , 94:4937-4942 (1997)
	Harding et al., "CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones," <i>Nature</i> , 356:607-609 (1992)
	Harper et al., "CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location," <i>J Immunol</i> , 147:1037-1044 (1991)
	Hathcock et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," <i>Science</i> , 262:905-907 (1993)
	Hofmann et al., "A model of Cdc25 phosphatase catalytic Domain and Cdk-interaction surface based on the presence of a rhodanese homology domain," <i>J Mol Biol</i> , 282:195-208 (1998)
	Holliger et al., "Diabodies": Small bivalent and bispecific antibody fragments," <i>PNAS USA</i> 90:6444-6448 (1993)
	Hoogenboom et al., "Building antibodies from their genes," <i>Immunol. Reviews</i> , 130:43-68 (1992)
	Horspool et al., "Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4," <i>J Immunol</i> , 160:2706-2714 (1998)
	Houghten, "General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids," <i>Proc Natl Acad Sci USA</i> , 82:5131-5135 (1985)
I.O.	Houghten et al., "The use of synthetic peptide combinatorial libraries for the identification of bioactive peptides," <i>Biotechniques</i> , 13:412-421 (1992)

EXAMINER

Ilia Ouspewski

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANTS	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
	APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
	FILING DATE July 1, 2003	GROUP 4446 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
J.O.	Hurwitz et al., "Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis," <i>J Neuroimmunol</i> , 73:57-82 (1997)
	Hurwitz et al., "CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma," <i>Proc Natl Acad Sci USA</i> , 95:10067-10071 (1998)
	Ill et al., "Design and construction of a hybrid immunoglobulin domain with properties of both heavy and light chain variable regions," <i>Protein Engineering</i> , 10:949-957 (1997)
	Jakobovits et al., "Germ-line transmission and expression of a human-derived yeast artificial-chromosome," <i>Nature</i> , 362:255-258 (1993)
	Jakobovits, et al., "Analysis of homozygous mutant chimeric mice: Deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production," <i>Proc. Natl. Acad. Sci. USA</i> , 90:2551-2555 (1993)
	Jakobovits, "Humanizing the mouse genome," <i>Current Biology</i> , 4:761-763 (1994)
	Jakobovits, "Production of fully human antibodies by transgenic mice," <i>Current Opinion in Biotechnology</i> , 6:561-566 (1995)
	Jakobovits, "The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice," <i>Expert Opinion on Investigational Drugs</i> , 7:607-614 (1998)
	Joukov et al., "Identification of Csk tyrosine phosphorylation sites and a tyrosine residue important for kinase domain structure," <i>Biochem J</i> , 322:927-935 (1997)
	Junghans et al., "Antibody-based immunotherapies for cancer," <i>Cancer Chemotherapy and Biotherapy</i> , 655-686 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996))
	Kostelny et al., "Formation of a bispecific antibody by the use of leucine zippers," <i>J. Immunol.</i> , 148:1547-1553 (1992)
	Krummel and Allison, "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation," <i>J Exp Med</i> , 182:459-465 (1995)
	Krummel et al., "Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo," <i>Int Immunol</i> , 8:519-523 (1996)
J.O.	Kuchroo et al., "B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy," <i>Cell</i> , 80:707-718 (1995)

EXAMINER

Ilia Ouspenski

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANTS	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
	APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
	FILING DATE July 1, 2003	GROUP 4416 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
J.O.	Kwon et al., "Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer," <i>Proc Natl Acad Sci USA</i> , 94:8099-8103 (1997)
	LaPlanche et al., "Phosphorothioate-modified oligodeoxynucleotides. III NMR and UV spectroscopic studies of the R _p -R _p , S _p -S _p duplexes. [d(GG ₂ AATTCC) ₂] ₂ derived from diastereomeric O-ethyl phosphorothioates," <i>Nucl. Acids Res.</i> , 14:9081 (1986)
	Lenschow et al., "Expression and functional significance of an additional ligand for CTLA-4," <i>Proc Natl Acad Sci USA</i> , 90:11054-11058 (1993)
	Lenschow et al., "Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg," <i>Science</i> , 257:789-792 (1992)
	"Leucocyte Typing VI: White Cell Differentiation Antigens," <i>Garland Publishing</i> , New York, NY, pp 30-31, 95-98 and 1213-1214.
	Lin et al., "Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28," <i>J Exp Med</i> , 188:199-204 (1998)
	Linsley et al., "CTLA-4 is a second receptor for the B cell activation antigen B7," <i>J. Exp. Med.</i> , 174:561-569 (1991)
	Linsley et al., "Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes," <i>J Exp Med</i> , 176:1595-1604 (1992)
	Linsley et al., "Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule," <i>Science</i> , 257:792-795 (1992)
	Liu et al., "Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity," <i>J. Immunol.</i> , 139:3521-3528 (1987)
	Liu et al., "Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells," <i>Proc Natl Acad Sci USA</i> , 84:3439-3443 (1987)
	Lonberg et al., "Antigen-specific human antibodies from mice comprising four distinct genetic modifications," <i>Nature</i> , 368:856-859 (1994)
	Löhrer et al., "Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes," <i>J Exp Med</i> , 187:427-432 (1998)
J.O.	Mandel et al., "ABGEN: A knowledge-based automated approach for antibody structure modeling," <i>Nature Biotechnology</i> , 14:323-328 (1996)

EXAMINER

Dina Onspenshi

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
INFORMATION DISCLOSURE STATEMENT BY APPLICANTS		APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
		FILING DATE July 1, 2003	GROUP 4418 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
J.O.	Marasco, "Intrabodies: turning the humoral immune system outside in for intracellular immunization," <i>Gene Therapy</i> , 4:11-15 (1997)
	Markees et al., "Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon- γ , and CTLA4," <i>J Clin Invest</i> , 101:2446-2455 (1998)
	Marks et al., "Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes," <i>Eur. J. Immunol.</i> , 21:885-891 (1991)
	Marrack, et al., "The Staphylococcal Enterotoxins and Their Relatives," <i>Science</i> , 705-711 (1980)
	Martin et al., "The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6," <i>The EMBO Journal</i> , 13:5303-5309 (1994)
	McCoy et al., "Protective immunity to nematode infection is induced by CTLA-4 blockade," <i>J Exp Med</i> , 186:183-187 (1997)
	Mendez et al., "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice," <i>Nature Genetics</i> , 15:146-166 (1997)
	Monfardini et al., "Rational design, analysis, and potential utility of GM-CSF antagonists," <i>Proc Assoc Am Physicians</i> , 108:420-431 (1996)
	Murphy et al., "Blockade of CTLA-4 enhances host resistance to the intercellular pathogen, <i>Leishmania donovani</i> ," <i>J. Immunol.</i> , 161:4153-4160 (1998)
	Needleman and Wunsch, "A general method applicable to the search for similarities in the amino acid sequence to two proteins," <i>Mol. Biol.</i> , 48:443-453 (1970)
	Okayama et al., "A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells," <i>Mol. Cell. Bio.</i> , 3:280-289 (1983)
	Parnley and Smith, "Antibody-selectable filamentous fd phage vectors: affinity purification of target genes," <i>Gene</i> , 73:305-318 (1988)
	Pearson and Lipman, "Improved tools for biological sequence comparison," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 85:2444-2448 (1988)
	Perez et al., "Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement," <i>Immunity</i> , 6:411-417 (1997)
J.O.	Perrin et al., "B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis," <i>Immunol Res</i> , 14:189-199 (1995)

EXAMINER

Ilia Aspenshi

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	APPLICATION NO.
		ABX-PF1 DIV1	10/612,497
		APPLICANTS	CONFIRMATION NO.
		Douglas C. Hanson et al.	3552
INFORMATION DISCLOSURE STATEMENT BY APPLICANTS		FILING DATE	GROUP
		July 1, 2003	4116 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
J.O.	Perrin et al., "CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis" <i>J Immunol</i> , 157:1333-1336 (1996)
	Pinilla et al., "Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries," <i>Biotechniques</i> , 13:901-905 (1992)
	Powell et al., "Compendium of excipients for parenteral formulations," <i>PDA J Pharm Sci Technol</i> , 62:238-311 (1998)
	Razi-Wolf et al., "Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor," <i>Proc Natl Acad Sci USA</i> , 90:11182-11186 (1993)
	Rizo and Gierasch, "Constrained peptides: models of bioactive peptides and protein substructure," <i>Ann. Rev. Biochem.</i> , 61:387-418 (1992)
	Russel et al., "Retroviral vectors displaying functional antibody fragments," <i>Nucl. Acids Research</i> , 21:1081-1085 (1993)
	Schwartz, "Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy," <i>Cell</i> , 71:1065-1068 (1992)
	Scott, "Discovery peptide ligands using epitope libraries," <i>Trends In Biochemical Sciences</i> , 17:241-245 (1992)
	Singh et al., "Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases," <i>J Med Chem</i> , 40:1130-1136 (1997)
	Smith and Waterman, "Comparison of Blosequences," <i>Adv. Appl. Math.</i> , 2:482-489 (1981)
	Songsvilai and Lachmann, "Bispecific antibody: a tool for diagnosis and treatment of disease," <i>Clin. Exp. Immunol.</i> , 79: 315-321 (1990)
	Stec et al., "Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides," <i>J. Am. Chem. Soc.</i> , 106:6077-6079 (1984)
	Stein et al., "Physicochemical properties of phosphorothioate oligodeoxynucleotides," <i>Nucl. Acids Res.</i> , 16:3209-3221 (1988)
	Taylor et al., "A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins," <i>Nucleic Acids Research</i> , 20:6287-6295 (1992)
	Taylor et al., "Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM," <i>International Immunology</i> , 6:579-591 (1994)
J.O.	Thornton et al., "Prediction of progress at last" <i>Nature</i> , 354:105-106 (1991)

EXAMINER

Eric Auspewski

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANTS	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
	APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
	FILING DATE July 1, 2003	GROUP 4446 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
I.O.	Tivol et al., "Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4," <i>Immunity</i> , 3:541-547 (1995)
	Townsend and Allison, "Tumor rejection after direct costimulation of CD8 ⁺ T cells by B7-transfected melanoma cells," <i>Science</i> , 259:368-370 (1993)
	Trautenecker et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells," <i>EMBO J</i> , 10:3655-3659 (1991)
	Trautenecker et al., "Janusin: new molecular design for bispecific reagents," <i>Int. J. Cancer (Suppl.)</i> , 7:51-52 (1992)
	Tuaillon et al., "Analysis of direct and inverted DJH rearrangements in a human Ig heavy chain transgenic minilocus," <i>J. Immunol.</i> , 154:6453-6465 (1995)
	Tuaillon et al., "Human immunoglobulin heavy-chain minilocus recombination in transgenic mice: gene-segment use in μ and γ transcripts," <i>Proc. Natl. Acad. Sci. USA</i> , 90:3720-3724 (1993)
	Uhlmann and Peyman, "Antisense RNA: A natural gene expression control system," <i>Chemical Reviews</i> , 90:543 (1990)
	Van Parijs et al., "Role of interleukin 12 and costimulators in T cell anergy in vivo," <i>The Journal of Experimental Medicine</i> , 188, 1119-1128 (1997)
	Veber and Freidinger, "The design of metabolically-stable peptide analogs," <i>Trends In Neuro Sciences</i> , p.392 (1985)
	Vitetta et al., "Immunotoxins: magic bullets or misguided missiles," <i>Immunol Today</i> , 14:252-259 (1993)
	Walunas et al., "CTLA-4 can function as a negative regulator of T cell activation," <i>Immunity</i> , 1:405-413 (1994)
	Walunas et al., "CTLA-4 ligation blocks CD28-dependent T cell activation," <i>J Exp Med</i> , 183:2541-2550 (1996)
	Waterhouse et al., "Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4," <i>Science</i> , 270:985-988 (1995)
	Winter and Harris, "Humanized Antibodies," <i>Immunology Today</i> , 14:243-246 (1993)
	Wright et al., "Genetically engineered antibodies: Progress and prospects," <i>Crit. Reviews in Immunol.</i> , 12:125-168 (1992)
I.O.	Yang et al., "Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages," <i>Cancer Res</i> , 57:4036-4041 (1997)

EXAMINER

Ilia Auspensi

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANTS	ATTY. DOCKET NO. ABX-PF1 DIV1	APPLICATION NO. 10/612,497
	APPLICANTS Douglas C. Hanson et al.	CONFIRMATION NO. 3552
	FILING DATE July 1, 2003	GROUP 1116 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
J.O.	Yi-qun et al., "Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens," <i>Int Immunol</i> , 8:37-44 (1996)
J.O.	Zon et al., "Phosphorothioate oligonucleotides: chemistry, purification, analysis, scale-up and future directions," <i>Anti-Cancer Drug Design</i> , 6:539-568 (1991)
J.O.	Zon et al., "Phosphorothioate oligonucleotides," <i>Oligonucleotides and Analogues: A Practical Approach</i> , pp. 87-108 (F. Eckstein, Ed., Oxford University Press, Oxford England (1991))

EXAMINER

Ilion Aspenshi

DATE CONSIDERED

6/27/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicants.